Live Markets »News & Advice»Smart Moves»Smart Moves Details
Smart Moves Details

Neuland Laboratories dips 8% on disappointing Q2 earning

SI Reporter/Mumbai 23 Nov 17 | 10:25 AM
 Neuland Laboratories Ltd

BSE   20 Jun 19 | 12:00 AM

537.85  -8.95 (-1.64%)

NSE   20 Jun 19 | 12:00 AM

538.75  -8.2 (-1.5%)

Neuland Laboratories has dipped 8% to Rs 1,175 on the BSE in intra-day trade after the company reported 75% decline in its standalone net profit at Rs 2.59 crore in September quarter (Q2FY18), due to lower sales. The pharmaceutical company had profit of Rs 10.23 crore in the same quarter year ago.

Total operating income decreased by 17% to Rs 126 crore in Q2FY18, as compared to Rs 152 crore in the corresponding period of the previous year. EBITDA (earnings before interest, taxes, depreciation and amortization) margin fallen to 11.6% in Q2FY18 as against 16.6% in Q2FY17.

Related Stories

    No Related Stories Found
Widgets Magazine

“The performance of this quarter was impacted due to lower than expected sales in Ciprofloxacin, Salmeterol and a product in the CMS segment. Also, the company continues to face capacity constraints in Unit- 1 that prevented it from delivering more orders this quarter," said Sucheth Davuluri, Vice-Chairman and CEO, Neuland Laboratories.

The Board has given an in-principle approval to acquire a registered facility and we believe that this process when consummated will address capacity constraints as well as our growth aspirations, added Sucheth Davuluri.

At 10:23 AM; the stock was down 7% at Rs 1,188 on the BSE, against a marginal 0.02% rise in the S&P BSE Sensex. A combined 27,159 shares changed hands on the counter on the NSE and BSE.

Widgets Magazine


Company Price Gain (%)
Yes Bank114.5510.94
Sun Pharma.Inds.390.604.01
IndusInd Bank1,435.503.80
Larsen & Toubro1,556.153.36
ICICI Bank433.353.20


Currently No Poll Available.

Online Portfolio

You can create Online Portfolio here using the below button.

Widgets Magazine